None

HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, today announced its name change (from Pluristem Therapeutics Inc. Nasdaq: PSTI), reflecting a broader strategy of leveraging its 3D cell expansion technology to develop innovative cell-based products that can be harnessed for a range of fields beyond medicine, providing solutions for various areas of the life sciences. As of July 26, 2022, Pluri will begin trading on Nasdaq under the new ticker symbol “PLUR,” CUSIP number 72942G 104.

Related tickers: PSTI.

Yesterday Pluristem Therapeutics Inc (NASDAQ: PSTI) announced top-line results from its Phase 3 trial evaluating PLX-PAD in 240 patients for muscle recovery following hip fracture surgery.  HC wainwright believes the muscle strength results from the Phase 3 trial confirm the results seen in the Phase 1/2 trial, in which increases in gluteus medius strength and volume were observed at 26 weeks post-treatment. The analyst reiterates a Buy rating with a price target of $10. Related: Pluristem Posts Mixed Results From ...Full story available on Benzinga.com

Related tickers: PSTI.